ReviewFrontiers in oncology2020

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics.

Jiun-I Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.